Loading
A phase 3 trial of Carfilzomib, Pomalidomide, Elotuzumab in multiple myeloma, run by AbbVie, active and no longer recruiting.
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06158841 by AbbVie, with 421 participants enrolled, started 2024-05-19 and due to reach its primary completion in 2027-12. Interventions recorded: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Elotuzumab, Carfilzomib, Pomalidomide, Bortezomib.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Elotuzumab, Carfilzomib, Bortezomib, Dexamethasone.
Shares Selinexor, Pomalidomide, Bortezomib, Dexamethasone.
Shares Selinexor, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone, Relapsed or refractory multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/